CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis

Human Pathology

Volumn 44, Issue 9, 2013, Pages 1882-1889

  Zhang, Jing ^a,b   Chang, Bin ^a,c   Liu, Jinsong ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CD44; Immunohistochemistry; Ovarian carcinoma; Prognosis

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; STAINING; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA;

CD44; IMMUNOHISTOCHEMISTRY; OVARIAN CARCINOMA; PROGNOSIS;

ADENOCARCINOMA; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TEXAS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84883446760     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.02.016     Document Type: Article

References (34)

1. O. Nagano, D. Murakami, and D. Hartmann Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation J Cell Biol 165 2004 893 902
2. D. Naor, R.V. Sionov, and D. Ish-Shalom CD44: structure, function, and association with the malignant process Adv Cancer Res 71 1997 241 319
3. R. Marhaba, and M. Zoller CD44 in cancer progression: adhesion, migration and growth regulation J Mol Histol 35 2004 211 231
4. N.E. Stavropoulos, I. Filliadis, and E. Ioachim CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors Int Urol Nephrol 33 2001 479 483
5. O. Watanabe, J. Kinoshita, and T. Shimizu Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer J Exp Clin Cancer Res 24 2005 75 82
6. A. Lugli, G. Iezzi, and I. Hostettler Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer Br J Cancer 103 2010 382 390
7. M.D. Curley, L.A. Garrett, J.O. Schorge, R. Foster, and B.R. Rueda Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer Front Biosci 16 2011 368 392
8. (-/low)/CD44+ breast cancer-initiating cells to radiation J Natl Cancer Inst 98 2006 1777 1785
9. L.J. Ling, S. Wang, and X.A. Liu A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone Chin Med J (Engl) 121 2008 1980 1986
10. H. Tanaka, M. Nakamura, and C. Kameda The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells Anticancer Res 29 2009 2147 2157
11. M.F. Shi, J. Jiao, and W.G. Lu Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line Cell Mol Life Sci 67 2010 3915 3925
12. P. Chu, D.J. Clanton, and T.S. Snipas Characterization of a subpopulation of colon cancer cells with stem cell-like properties Int J Cancer 124 2009 1312 1321
13. L. Patrawala, T. Calhoun, and R. Schneider-Broussard Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells Oncogene 25 2006 1696 1708
14. S. Sillanpaa, M.A. Anttila, and K. Voutilainen CD44 expression indicates favorable prognosis in epithelial ovarian cancer Clin Cancer Res 9 2003 5318 5324
15. N. Zagorianakou, D. Stefanou, and G. Makrydimas CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival Anticancer Res 24 2004 1665 1670
16. E.Y. Cho, Y. Choi, S.W. Chae, J.H. Sohn, and G.H. Ahn Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms Pathol Int 56 2006 62 70
17. F.A. Tavassoeli, and P. Devilee Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003 IARC press Lyon 117 145
18. P. Russell The pathological assessment of ovarian neoplasms. I: Introduction to the common 'epithelial' tumours and analysis of benign 'epithelial' tumours Pathology 11 1979 5 26
19. P. Russell The pathological assessment of ovarian neoplasms. II: The proliferating 'epithelial' tumours Pathology 11 1979 251 282
20. P. Russell The pathological assessment of ovarian neoplasms. III: The malignant "epithelial" tumours Pathology 11 1979 493 532
21. A. Malpica, M.T. Deavers, and K. Lu Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
22. J.H. Shepherd Revised FIGO staging for gynaecological cancer Br J Obstet Gynaecol 96 1989 889 892
23. G.J. Rustin, A.E. Nelstrop, and M. Crawford Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125 J Clin Oncol 15 1997 172 176
24. G.J. Rustin, A.E. Nelstrop, M.K. Tuxen, and H.E. Lambert Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study Ann Oncol 7 1996 361 364
25. D.G. Rosen, G. Yang, and M.T. Deavers Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma Cancer 106 2006 1925 1932
26. L. Rodriguez-Rodriguez, I. Sancho-Torres, C. Mesonero, D.G. Gibbon, W.J. Shih, and G. Zotalis The CD44 receptor is a molecular predictor of survival in ovarian cancer Med Oncol 20 2003 255 263
27. A.M. Afify, A.W. Ferguson, R.M. Davila, and B.A. Werness Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas Appl Immunohistochem Mol Morphol 9 2001 309 314
28. H.S. Berner, B. Davidson, and A. Berner Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma - diagnostic and prognostic implications Clin Exp Metastasis 18 2000 197 202
29. J.B. Catterall, L.M. Jones, and G.A. Turner Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan Clin Exp Metastasis 17 1999 583 591
30. J.R. Teyssier, P. Couillin, J. Benard, N. Ravisse, E. Ulrich, and P. Cornillet A multidrug-resistant ovarian carcinoma cell line with a malignant suppressed phenotype is a CD44 gene expression defective mutant Cancer Genet Cytogenet 60 1992 14 19
31. J.S. Ross, C.E. Sheehan, S.S. Williams, J.H. Malfetano, W.M. Szyfelbein, and B.V. Kallakury Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas Am J Clin Pathol 116 2001 122 128
32. L.Y. Bourguignon, E. Gilad, K. Rothman, and K. Peyrollier Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression J Biol Chem 280 2005 11961 11972
33. T. Strobel, L. Swanson, and S.A. Cannistra In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation Cancer Res 57 1997 1228 1232
34. K. Lessan, D.J. Aguiar, T. Oegema, L. Siebenson, and A.P. Skubitz CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells Am J Pathol 154 1999 1525 1537